Prelude Therapeutics (PRLD) Share-based Compensation (2019 - 2026)

Prelude Therapeutics has disclosed Share-based Compensation across 8 years of filings, most recently posting $2.0 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.0 million, down 47.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (down 48.64% YoY), and the FY2025 annual result was $11.9 million, down 44.19% from the prior year.
• Share-based Compensation came in at $2.0 million for Q1 2026 at Prelude Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.8 million in Q1 2022 to a low of $1.8 million in Q4 2025.
• The 5-year median for Share-based Compensation is $5.9 million (2023), against an average of $5.1 million.
• Across the five-year window, Share-based Compensation soared 42.27% in 2022 and plunged 59.11% in 2025, its largest moves.
• Prelude Therapeutics' Share-based Compensation stood at $5.8 million in 2022, then climbed by 1.15% to $5.9 million in 2023, then plunged by 36.16% to $3.8 million in 2024, then tumbled by 51.14% to $1.8 million in 2025, then advanced by 8.46% to $2.0 million in 2026.
• The last three Share-based Compensation figures came in at $2.0 million (Q1 2026), $1.8 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.